Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on July 11)
- AC Immune SA (NASDAQ: ACIU)
- Arbutus Biopharma Corp (NASDAQ: ABUS)
- DexCom, Inc. (NASDAQ: DXCM)
- Eagle Pharmaceuticals Inc (NASDAQ: EGRX)
- Illumina, Inc. (NASDAQ: ILMN)
- Intuitive Surgical, Inc. (NASDAQ: ISRG)
- Krystal Biotech Inc (NASDAQ: KRYS)
- Myriad Genetics, Inc. (NASDAQ: MYGN) (Morgan Stanley analyst Steve Beuchaw upgraded shares to Overweight and hiked his price target to $55.
Down In The Dumps
(Stocks hitting 52-week lows on July 11)
- Advaxis, Inc. (NASDAQ: ADXS)(announced withdrawal of Conditional Marketing Authorization ApplIcation in Europe for axalimogene filolisbac to treat metastatic cervical cancer in patients who progress beyond first-line therapy. This follows EMA's determination that additional data is required for conditional approval.)
- Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL)
- Calithera Biosciences Inc (NASDAQ: CALA)
- Catabasis Pharmaceuticals Inc (NASDAQ: CATB)
- Cytori Therapeutics Inc (NASDAQ: CYTX)
- Idera Pharmaceuticals Inc (NASDAQ: IDRA)(terminated merger agreement with BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX))
- Reshape Lifesciences Inc (NASDAQ: RSLS)(announced $2.7 million registered direct offering)
- Sellas Life Sciences Group Inc (NASDAQ: SLS)
Stocks In Focus AbbVie Files For Expanded Indication For Its Blood Cancer Drug
AbbVie Inc (NYSE: ABBV) said it has submitted a sNDA for its Venetoclax n combination with a hypomethylating agent or in combination with low-dose cytarabine for treating newly diagnosed acute myeloid leukemia, or AML, patients ineligible for intensive chemotherapy. The treatment option has already been approved for chronic lymphocytic leukemia.
The application has been submitted based on a Phase 1b as well as a Phase 1/2 trial.
Final Mid-stage Results of Sanofi's TB Vaccines Published In NEJM
A Phase 2 proof-of-concept study of two vaccinations, namely the existing BCG vaccine as well as an investigational vaccine, H4:IC31, developed by Sanofi SA (ADR)(NYSE: SNY) along with Aeras, a NGO, showed that BCG significantly reduced sustained TB infections in adolescents with a 45.4 percent vaccine efficacy. H4:IC31 also reduced sustained infections, although not at statistically significant levels, showing 30.5% vaccine efficacy.
"However, the trend observed for H4:IC31 is the first time a subunit vaccine has shown any signal that it may be able to protect against TB infection or disease in humans," the company said.
The final results were published in the New England Journal of Medicine.
Illumina's Leverages Its Technology to OrigiMed
OrigiMed announced an agreement with Illumina, Inc. (NASDAQ: ILMN) that provides for the former developing and promoting its advanced molecular clinical tumor applications to the public in China using the latter's Next Generation Sequencing, or NGS, technology.
"It also signals that genomics technology will play an increasingly important future role in the fast-developing market of precise diagnosis of cancer," OrigiMed said.
Aurinia Initiates Mid-stage Trial For Dry Eye Syndrome
The company said the trial is evaluating the tolerability of VOS 0.2 percent versus Restasis at four weeks in subjects with mild to moderate DES.
The stock rose 2.8 percent to $5.87 in after-hours trading.
AcelRx, Myovant Announce Common Stock Offerings
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced the commencement of an underwritten public offering of its common stock, with all the shares to be sold the company. The company did not divulge the size of the offering.
Myovant Sciences Ltd (NYSE: MYOV) said it has commenced a $75 million common stock offering. The company intends to use the proceeds for the commercial launch of relugolix, its pipeline candidate for endometriosis and uterine fibroids, as well as for working capital and other general corporate purposes.
AcelRx shares fell 7.35 percent to $3.15 in after-hours trading and Myovant slumped 17.01 percent to $20.
On The Radar
FDA's Antimicrobial Drugs Advisory Committee is set to discuss GlaxoSmithKline plc (ADR) (NYSE: GSK)'s NDA for tafenoquine tablet, 150 milligram indicated for radical cure, ie prevention of relapse, of Plasmodium vivax malaria on July 12.
FDA Commissioner Scott Gottlieb issued a statement, wherein he discussed the agency's efforts to advance development of gene therapies, which according to the agency, have the potential treat intractable and vexing diseases. The FDA released a suite of six scientific guidance documents in draft form, meant to serve as the building blocks of a comprehensive framework.
See more from Benzinga
- Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares
- Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage
- The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.